ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 232 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,671 | -13.1% | 704 | -0.1% | 0.00% | – |
| Q2 2023 | $16,885 | -31.5% | 705 | -46.2% | 0.00% | – |
| Q1 2023 | $24,654 | +53.2% | 1,310 | +29.6% | 0.00% | – |
| Q4 2022 | $16,095 | -19.5% | 1,011 | -17.6% | 0.00% | – |
| Q3 2022 | $20,000 | -9.1% | 1,227 | -20.4% | 0.00% | – |
| Q2 2022 | $22,000 | -69.9% | 1,541 | -49.0% | 0.00% | – |
| Q1 2022 | $73,000 | +28.1% | 3,022 | +23.5% | 0.00% | – |
| Q4 2021 | $57,000 | -17.4% | 2,447 | -40.9% | 0.00% | – |
| Q3 2021 | $69,000 | -37.8% | 4,138 | -9.1% | 0.00% | – |
| Q2 2021 | $111,000 | +7.8% | 4,553 | +14.3% | 0.00% | – |
| Q1 2021 | $103,000 | -49.0% | 3,984 | +4.8% | 0.00% | – |
| Q4 2020 | $202,000 | +1.0% | 3,803 | -21.7% | 0.00% | – |
| Q3 2020 | $200,000 | -14.2% | 4,854 | +1.0% | 0.00% | -100.0% |
| Q2 2020 | $233,000 | -0.4% | 4,804 | -13.3% | 0.00% | 0.0% |
| Q1 2020 | $234,000 | +47.2% | 5,538 | +48.9% | 0.00% | – |
| Q4 2019 | $159,000 | +231.2% | 3,720 | +176.4% | 0.00% | – |
| Q3 2019 | $48,000 | +300.0% | 1,346 | +181.6% | 0.00% | – |
| Q2 2019 | $12,000 | -57.1% | 478 | -55.4% | 0.00% | – |
| Q1 2019 | $28,000 | +7.7% | 1,072 | -33.2% | 0.00% | – |
| Q4 2018 | $26,000 | -25.7% | 1,604 | -3.7% | 0.00% | – |
| Q3 2018 | $35,000 | +3400.0% | 1,666 | +2092.1% | 0.00% | – |
| Q2 2018 | $1,000 | -90.9% | 76 | -84.0% | 0.00% | – |
| Q1 2018 | $11,000 | -75.0% | 475 | -67.7% | 0.00% | – |
| Q4 2017 | $44,000 | -30.2% | 1,470 | -13.2% | 0.00% | – |
| Q3 2017 | $63,000 | +125.0% | 1,693 | +68.8% | 0.00% | – |
| Q2 2017 | $28,000 | +115.4% | 1,003 | +174.0% | 0.00% | – |
| Q1 2017 | $13,000 | +44.4% | 366 | +15.1% | 0.00% | – |
| Q4 2016 | $9,000 | +200.0% | 318 | +218.0% | 0.00% | – |
| Q3 2016 | $3,000 | 0.0% | 100 | 0.0% | 0.00% | – |
| Q2 2016 | $3,000 | 0.0% | 100 | 0.0% | 0.00% | – |
| Q1 2016 | $3,000 | -94.3% | 100 | -93.3% | 0.00% | – |
| Q4 2015 | $53,000 | -15.9% | 1,493 | -21.2% | 0.00% | – |
| Q3 2015 | $63,000 | -4.5% | 1,895 | +20.3% | 0.00% | – |
| Q2 2015 | $66,000 | +633.3% | 1,575 | +496.6% | 0.00% | – |
| Q1 2015 | $9,000 | +12.5% | 264 | 0.0% | 0.00% | – |
| Q4 2014 | $8,000 | -79.5% | 264 | -83.2% | 0.00% | – |
| Q1 2014 | $39,000 | 0.0% | 1,575 | +1.7% | 0.00% | – |
| Q4 2013 | $39,000 | – | 1,548 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |